Literature DB >> 12401582

Halothane, isoflurane, and fentanyl increase the minimally effective defibrillation threshold of an implantable cardioverter defibrillator: first report in humans.

Avi A Weinbroum1, Aharon Glick, Yitzchak Copperman, Tamar Yashar, Valery Rudick, Ron Flaishon.   

Abstract

UNLABELLED: Placing an implantable cardioverter defibrillator (ICD) involves the induction of ventricular fibrillation, whereupon the minimally effective defibrillation energy threshold (DFT) is determined. We evaluated the effects of 0.7% halothane, 1% isoflurane, or 1.5 micro g/kg of IV fentanyl during N(2)O/oxygen-based general anesthesia (GA) or those of subcutaneous 1.5% lidocaine plus IV 0.35 mg/kg of propofol on the DFT during ICD implantation in humans (n = 20 per group). Thirty minutes after the first set of DFT measurements under such conditions, the inhaled anesthetics were withdrawn, and all three GA groups received fentanyl 1 microg/kg IV (second set). A third set was taken 30 min later, before the GA patients awakened and when only N(2)O/oxygen was delivered for GA. The lidocaine plus propofol patients were given the same IV propofol bolus 1 min before each fibrillation/defibrillation trial and at the same time points as the three GA groups. The first DFTs were 16.1 +/- 2.2 J (halothane), 17.7 +/- 2.7 J (isoflurane), 16.4 +/- 2.9 J (fentanyl), and 12.9 +/- 3.8 J (lidocaine plus propofol) (P = 0.01). The second set of DFTs were significantly lower than the first sets for the halothane (P = 0.01) and isoflurane (P = 0.02), but not the fentanyl or lidocaine plus propofol, regimens. The third DFTs were significantly (P < 0.01) lower than the first ones for the three GA groups, but not for the lidocaine plus propofol patients. Thus, halothane, isoflurane, and fentanyl increased DFT values during ICD implantation in humans, whereas lidocaine plus intermittent small-dose IV propofol minimized these thresholds. IMPLICATIONS: Halothane, isoflurane, and IV fentanyl added to N(2)O/oxygen-based general anesthesia similarly increase minimal defibrillation threshold energy requirements (DFT) during cardioverter defibrillator implantation in humans. Subcutaneous lidocaine plus intermittent small-dose IV propofol minimizes DFT compared with these general anesthetics while providing equal patient satisfaction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401582     DOI: 10.1097/00000539-200211000-00004

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  5 in total

Review 1.  [Implantation of cardioverter-defibrillators. How much anesthesia is necessary?].

Authors:  T Sellmann; M Winterhalter; U Herold; P Kienbaum
Journal:  Anaesthesist       Date:  2010-06       Impact factor: 1.041

2.  Effect of substance abuse on defibrillation threshold in patients with implantable cardioverter-defibrillator.

Authors:  Shane A Perrine; Raghavendra Nayak; Aditya S Bharadwaj; George McKelvey; Tamam Mohamad; Sony Jacob
Journal:  Pacing Clin Electrophysiol       Date:  2010-10-14       Impact factor: 1.976

Review 3.  Effect of drugs on defibrillation capacity.

Authors:  Anna Legreid Dopp; John M Miller; James E Tisdale
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  High defibrillation threshold: the science, signs and solutions.

Authors:  Sony Jacob; Victorio Pidlaoan; Jaspreet Singh; Aditya Bharadwaj; Mehul B Patel; Antonio Carrillo
Journal:  Indian Pacing Electrophysiol J       Date:  2010-01-07

5.  Incidence of ineffective safety margin testing (<10 J) and efficacy of routine subcutaneous array insertion during implantable cardioverter defibrillator implantation.

Authors:  Marc-Alexander Ohlow; Marcus Roos; Bernward Lauer; J Christoph Geller
Journal:  Indian Pacing Electrophysiol J       Date:  2016-02-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.